Keyphrases
Obsessive-compulsive Disorder
100%
Adolescent Patients
100%
Fluvoxamine
100%
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
22%
Israel
11%
United States
11%
Depressive Symptoms
11%
Major Depressive Disorder
11%
Hallucinations
11%
Selective Serotonin Reuptake Inhibitors
11%
Hyperactivity
11%
Short-term Treatment
11%
Beck Depression inventory-II (BDI-II)
11%
Countries Worldwide
11%
Nausea
11%
Dose-ranging
11%
Daily Dose
11%
Tremor
11%
Overt Aggression
11%
Anorexic
11%
Monocyclic
11%
Open-label Trial
11%
Insomnia
11%
Suicide Potential
11%
Anorectic
11%
Bulimic Symptoms
11%
Dermatitis
11%
Global Adjustment
11%
Affective Spectrum
11%
Nursing and Health Professions
Obsessive Compulsive Disorder
100%
Fluvoxamine
100%
Symptom
44%
Side Effect
33%
Adolescent
22%
Yale Brown Obsessive Compulsive Scale
22%
Major Depression
11%
Hallucination
11%
Drug Therapy
11%
Hyperactivity
11%
Nausea
11%
Beck Depression Inventory
11%
Short Course Therapy
11%
Dermatitis
11%
Open-Label Trial
11%
Selective Serotonin Reuptake Inhibitor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Fluvoxamine
100%
Obsessive Compulsive Disorder
100%
Symptom
44%
Side Effect
33%
Hyperactivity
11%
Open-Label Trial
11%
Selective Serotonin Reuptake Inhibitor
11%
Nausea
11%
Major Depression
11%
Dermatitis
11%
Hallucination
11%
Neuroscience
Obsessive-Compulsive Disorder
100%
Fluvoxamine
100%
Major Depressive Disorder
11%
Beck Depression Inventory
11%
Tremor
11%
Cell Excitability
11%
Hyperactivity
11%
Open-Label Trial
11%
Selective Serotonin Reuptake Inhibitor
11%
Hallucination
11%
Psychology
Adolescents
100%
Obsessive-Compulsive Disorder
100%
Cell Excitability
20%
Hallucination
20%
Depression
20%
Beck Depression Inventory
20%